| Project/Area Number |
15K19600
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | University of Tsukuba |
|---|
Principal Investigator |
IMAGAWA Kazuo 筑波大学, 医学医療系, 助教 (40708509)
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Keywords | 黄疸 / 遺伝性肝疾患 / iPS細胞 / 胆汁うっ滞 / 再生医学 |
|---|
| Outline of Final Research Achievements |
To develop novel therapy for progressive familial intrahepatic cholestasis type 2, we attempted to establish a PFIC2 model by using iPSC technology. We generated the induced pluripotent stem cells from the patients with progressive familial intrahepatic cholestasis type 2. Then, the induced pluripotent stem cells were differentiated into hepatocyte-like cells. The hepatocyte-like cells expressed albumin, and formed bile canaliculi. The biliary excretion capacity of hepatocyte-like cells was impaired. The biliary excretion capacity of the BD-HLCs could be increased by 4PBA treatment. These results suggested that the drug efficacy could be evaluated by using BD-HLCs.
|
